Alentis Therapeutics remote jobs and company guide

Alentis Therapeutics is a clinical-stage biotech company focused on treating cancer and reversing fibrosis by targeting Claudin-1 (CLDN1). Across its pipeline, the team advances anti-Claudin-1 monoclonal antibodies and antibody-drug conjugates (ADCs) designed to specifically bind exposed CLDN1 in tumors and fibrotic tissue. The company’s mission is to unlock the broad therapeutic potential of Claudin-1 - an important target that is overexpressed and exposed outside tight junctions in both fibrosis and many cancers.

At the core of Alentis’ approach is a translation-focused Claudin-1 program built from founder-led research. The company describes its leadership team and broader organization as values-driven, emphasizing collaboration, hard work, and a shared belief that anti-Claudin-1 therapies can make a meaningful difference for patients. Alentis’ clinical development includes ADC candidates such as ALE.P02 and ALE.P03 for CLDN1+ oncology indications, and the fibrosis program through Lixudebart (formerly ALE.F02), aiming to preserve or restore organ function by addressing fibrotic signaling and the collagen barrier.